---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008337"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:29:37.635419+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt

## Summary
- Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.
- Cash and equivalents $1.3M as of March 31, 2024; additional $3.3M from equity post-quarter.
- Signed non-binding term sheet for $7.5M debt to replace toxic debt, with potential total up to $30M.
- Plans to file NDA for NRX-101 in bipolar depression with akathisia risk and for IV ketamine (HTX-100) by July 2024.
- Hope Therapeutics spinout planned; term sheets received from anchor investors for $60M investment.

## SEC filing metadata
- accession: 0001558370-24-008337
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/nrxp-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008337
- JSON: https://secwatch.observer/filing/0001558370-24-008337.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008337.txt

## Key facts
- Earnings Releases
  NRX Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2024.
  - Period: quarter ended March 31, 2024
  - Result: reported results
  source text: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm
- Earnings Releases
  NRX Pharmaceuticals, Inc. reported financial results for first quarter ending March 31, 2024.
  - Period: first quarter ending March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ending March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000155837024008337/0001558370-24-008337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.